Lorraine L. Rosamilia, MD

Dr. Rosamilia is from the Department of Dermatology, Geisinger Health System, State College, Pennsylvania.

Dr. Rosamilia reports no conflicts of interest in relation to this post.

The Journal of Investigative Dermatology recently published a Canadian population-based cohort study outlining the risk for inflammatory bowel disease (IBD) with isotretinoin use. It examined approximately 47,000 acne patients treated with isotretinoin, 185,000 patients treated with topical acne medications, and more than 1,500,000 untreated patients aged 12 to 29 years during a 12-year period. The authors concluded there was no primary association between isotretinoin and IBD but that subsets of patients on isotretinoin or topical acne therapy could be at risk; therefore, acne itself was postulated as the link.

Anthony M. Rossi, MD

Dr. Rossi is a Fellow in Procedural Dermatology and Mohs Surgery, Memorial Sloan-Kettering and Weill Cornell/New York-Presbyterian Hospital, both in New York, New York.

Dr. Rossi reports no conflicts of interest in relation to this post.

The September 2012 issue of Dermatologic Surgery (2012;38:1477-1489) featured a randomized controlled trial of 4 different fractionated ablative lasers used in the treatment of facial photoaging. The authors utilized 4 different lasers on 12 participants, with the treatment area being the face (divided into 4 quadrants). The lasers tested included the Fraxel Repair (Solta Medical Inc) fractionated CO₂ 10,600-nm laser, Active and Deep FX (Total FX; Lumenis) fractionated CO₂ 10,600-nm laser, Quadralase (Candela) fractionated CO₂ 10,600-nm laser, and Pearl Fractional (Fx; Cutera) fractionated yttrium-scandium-gallium-garnet (YSGG) 2790-nm laser.